(Q43565014)

24 November 2017

title

Fecal calprotectin levels predict the clinical course in patients with new onset of ulcerative colitis (English)

1 reference

24 November 2017

1 reference

5

1 reference

24 November 2017

2

Magnus Simrén

1 reference

24 November 2017

Anders Lasson

1

1 reference

24 November 2017

Per-Ove Stotzer

series ordinal

3

1 reference

24 November 2017

Stefan Isaksson

series ordinal

4

1 reference

24 November 2017

Hans Strid

series ordinal

6

1 reference

24 November 2017

publication date

1 March 2013

1 reference

Inflammatory Bowel Diseases

24 November 2017

published in

1 reference

24 November 2017

volume

19

1 reference

24 November 2017

issue

3

1 reference

24 November 2017

page(s)

576-581

1 reference

Ulcerative colitis: patient characteristics may predict 10-yr disease recurrence in a European-wide population-based cohort

24 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E31827E78BE

Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E31827E78BE

Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E31827E78BE

Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E31827E78BE

Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E31827E78BE

Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E31827E78BE

The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E31827E78BE

Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E31827E78BE

Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E31827E78BE

Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E31827E78BE

Infliximab, azathioprine, or combination therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E31827E78BE

10.1097/MIB.0B013E31827E78BE

21 January 2018

Identifiers

DOI

1 reference

24 November 2017

1 reference